


# The obesity market and GLP-1 agonists are transforming healthcare.


Here's a look at the current market...



Nearly 229 million people are considered overweight or living with obesity in the U.S.

Currently, 23% have a diagnosis of obesity (based on claims analysis), with 3.5% being prescribed a GLP-1 therapy.

Access to GLP-1 agonists for obesity continues to improve.



Social chatter, paid spend and earned media coverage are also increasing, driving unprecedented consumer demand.

Social media conversation volume QoQ

**+108.5%**

Paid media spend trend YoY

**+21%**

Earned media coverage volume QoQ

**+17.2%**

Leaders must prepare for the impacts GLP-1 agonists will have on health as we know it.

Don't know where to start?

**IRIS has you covered.**  
Let our insights-as-a-service platform bring you clarity.

Analyzes **billions of datapoints** to give you speed and agility

Aggregates **100+ proprietary metrics** and visualizes the analysis

User-friendly, live dashboard refreshed **52 weeks** a year

Provides a live dashboard with **12+ ways to filter data**

Delivers **10+ years of historical data** into usable formats

Dedicated multi-disciplinary expert team delivering **predictive analytics** that drive business impact

It's time to see.

Reach out to Shelly Cohn at [scohn@realchemistry.com](mailto:scohn@realchemistry.com) to access your IRIS dashboard and immersive insights reports.

Visit [realchemistry.com/transformational-healthcare-markets](https://realchemistry.com/transformational-healthcare-markets)